We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+12.78%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$208M
AUM Growth
+$29.3M
Cap. Flow
+$24.3M
Cap. Flow %
11.67%
Top 10 Hldgs %
53.69%
Holding
72
New
35
Increased
16
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.44M
2
DERM
Dermira, Inc.
DERM
+$4.69M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$4.6M
4
IRIX icon
IRIDEX
IRIX
+$4.41M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.88M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$9.36M
2
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$6.39M
3
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$5.51M
4
SBBP
Strongbridge Biopharma plc.
SBBP
+$4.51M
5
IMMU
Immunomedics Inc
IMMU
+$4.43M

Sector Composition

Rank Sector Weight
1 Healthcare 73.3%
2 Technology 1.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
26
Insmed
INSM
$21.3B
$2.17M 1.04%
+220,000
New +$2.57M
PACB icon
27
Pacific Biosciences
PACB
$441M
$2.11M 1.01%
300,000
+134,632
+81% +$1.23M
AGN
28
DELISTED
Allergan plc
AGN
$1.96M 0.94%
+8,500
New +$1.96M
CYNA
29
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$1.93M 0.93%
115,400
-475,130
-80% -$6.39M
NBIX icon
30
Neurocrine Biosciences
NBIX
$16.7B
$1.91M 0.92%
+42,000
New +$1.93M
PGNX
31
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$1.89M 0.91%
448,885
+216,085
+93% +$1.04M
TVTX icon
32
Travere Therapeutics
TVTX
$5.11B
$1.76M 0.85%
98,788
-101,212
-51% -$1.64M
EPIX
33
DELISTED
ESSA Pharma
EPIX
$1.75M 0.84%
28,512
+5,145
+22% +$321K
RIGL icon
34
Rigel Pharmaceuticals
RIGL
$693M
$1.67M 0.8%
74,775
-2,909
-4% -$72.3K
ATRC icon
35
AtriCure
ATRC
$1.97B
$1.6M 0.77%
+112,923
New +$1.72M
SRPT icon
36
CALL
Sarepta Therapeutics
SRPT
$1.68B
$1.53M 0.73%
+80,000
New +$1.48M
WBMD
37
DELISTED
WebMD Health Corp.
WBMD
$1.45M 0.7%
+25,000
New +$1.56M
CYTK icon
38
Cytokinetics
CYTK
$10.4B
$1.34M 0.64%
+140,969
New +$1.16M
SGY
39
PUT
DELISTED
Stone Energy
SGY
$1.3M 0.63%
+19,026
New +$761K
GHDX
40
DELISTED
Genomic Health, Inc.
GHDX
$1.26M 0.61%
+48,800
New +$1.3M
ASMB icon
41
Assembly Biosciences
ASMB
$503M
$1.25M 0.6%
+18,787
New +$1.23M
RXDX
42
DELISTED
Ignyta, Inc.
RXDX
$1.25M 0.6%
+229,748
New +$1.53M
ALIM
43
DELISTED
Alimera Sciences
ALIM
$1.2M 0.58%
64,955
– –
OLED icon
44
Universal Display
OLED
$3.67B
$1.02M 0.49%
15,000
-55,000
-79% -$3.38M
RPTP
45
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$938K 0.45%
+174,708
New +$896K
OTLK icon
46
Outlook Therapeutics
OTLK
$171M
$828K 0.4%
+1,521
New +$907K
SVA
47
DELISTED
Sinovac Biotech, Ltd
SVA
$786K 0.38%
+132,503
New +$812K
MRTX
48
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$683K 0.33%
125,000
+21,717
+21% +$346K
IRWD icon
49
Ironwood Pharmaceuticals
IRWD
$728M
$654K 0.31%
+59,700
New +$583K
BEAT
50
DELISTED
BioTelemetry, Inc.
BEAT
$564K 0.27%
+34,630
New +$509K
1
2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2016 Portfolio in Review

As of Q2 2016, Acuta Capital Partners held 72 positions worth $208M, up 16% from $179M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Acuta Capital Partners deployed $24.3M of net new capital in Q2 2016, opening 35 new positions and adding to 16 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 64,000 shares worth $4.98M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 69% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Amicus Therapeutics, an estimated $9.36M trimmed.

  • Acuta Capital Partners's largest Q2 2016 buy was BioMarin Pharmaceuticals: 64,000 shares worth $4.98M.
  • Acuta Capital Partners added most to Iovance Biotherapeutics in Q2 2016, an estimated $4.6M increase.
  • Acuta Capital Partners's biggest Q2 2016 reduction was Amicus Therapeutics, cutting an estimated $9.36M.
  • Acuta Capital Partners fully exited CELATOR PHARMACEUTICALS INC. COMMON STOCK in Q2 2016, selling an estimated $5.51M.
  • Acuta Capital Partners's ten largest holdings make up 54% of its $208M portfolio in Q2 2016.
  • Acuta Capital Partners opened 35 new positions and closed 7 in Q2 2016.
  • Acuta Capital Partners's portfolio value rose 16% quarter-over-quarter to $208M.

Based on Acuta Capital Partners's 13F filing for Q2 2016, filed 15 Aug 2016.